Expiration date: 09/2025
The composition and form of issue:
Capsules 1 capsule contains:
piracetam 400 mg
Cinnarizine 25 mg
excipients: lactose, silicon dioxide colloidal magnesium stearate
capsule shell: titanium dioxide, gelatin
in a contour acheikova packing 10 PCs. in cardboard pack 6 packs.
Description pharmaceutical form:
Capsule: solid, cylindrical, gelatin capsules white color .
The contents of the capsules: crystalline powder, white to pale cream color.
Feature:
The combined drugs.
Pharmacokinetics:
The drug is rapidly and completely absorbed in the digestive tract. Cmax piracetam in plasma is after 2-6 h, Cmax in cerebrospinal fluid is through 2-8 h. the Bioavailability is 100%. Plasma protein does not bind. Penetrates into all organs and tissues, passes the placental barrier. Selectively accumulates in the cerebral cortex, mainly in the frontal, parietal and occipital lobes, the cerebellum and the basal ganglia. Is not metabolized. After 30 h, more than 95% excreted by the kidneys. Cinnarizine Cmax in plasma is about 1-4 hours the plasma protein binds to 91%. Actively and completely metabolized. T1/2 is 4 h. 1/3 of the metabolites excreted in the urine, 2/3 in feces.
Description pharmacological action:
Piracetam activates the metabolic processes in the brain by enhancing the energy and protein metabolism, accelerate the utilization of glucose by cells and increase their resistance to hypoxia improves interneuronal transmission in the Central nervous system, improves regional blood flow in the ischemic area.
Cinnarizine — a selective blocker of the slow calcium channels, inhibits flow into cells calcium ions and reduces their maintenance depot plasmolemma reduces the tone of smooth muscles of arterioles and reduces their reaction to biogenic vasoconstrictor substances (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). Has vasodilator effect (particularly in relation to the blood vessels of the brain), increasing antihypoxia action piracetam and not having a significant impact on HELL. Exhibits moderate antihistaminic activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their deformation ability, reduces blood viscosity.
Indications:
Insufficiency of cerebral blood circulation (atherosclerosis of the brain, the recovery period of ischemic and hemorrhagic strokes, traumatic brain injury, encephalopathy of different Genesis).
Intoxication.
Other diseases of CNS, accompanied by decreasing intellectual-mental functions (memory impairment, attention, mood).
Psycho-organic syndrome with predominance of symptoms of fatigue and weakness, asthenic syndrome.
Labirintovaya, Meniere's disease.
The lag of intellectual development in children.
Prevention of migraine and kinetosis.
Contraindications:
Hypersensitivity, heavy human liver and/or kidney disease, Parkinson's disease, pregnancy, breastfeeding, children up to age 5 years.
With caution in Parkinson's disease.
Application of pregnancy and breast-feeding:
Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.
Side effects:
Dyspepsia, headache, and sleep disorders. Rarely, allergic reactions such as skin rash.
Drug interactions:
While admission may increase the sedative effect of oppressive Central nervous system activity, and alcohol, nootropic and hypotensive drugs. Vasodilators increase the effect of the drug. Improves tolerability of antipsychotic drugs and tricyclic antidepressants.
Method of application and dose:
Inside. Usual dose adults: 1-2 caps. 3 times a day for 1-3 months depending on the severity of the disease. The course of treatment — 2-3 times a year. Children (over 5 years) — 1-2 caps. 1-2 times a day. Do not apply more than 3 months.
Precautions:
The drug should be used with caution in persons with liver disease and/or kidney. In cases of mild and moderate renal failure (particularly if creatinine Cl <60 ml/min) should reduce therapeutic dose or increase the interval between doses. In individuals with abnormal liver function necessary to control the content of liver enzymes. Avoid drinking alcohol during treatment. The drug should be carefully prescribed for high intraocular pressure, as well as in Parkinson's disease. During treatment use caution when driving and working with machinery and equipment.
Special instructions:
Cinnarizine may cause a positive reaction at carrying out of doping tests in athletes.
It is possible to change the results of the determination of radioactive iodine (the dyes in the capsule shell contain iodine).
